top of page
Texture transparente

Les publications les plus récentes

Chabrun F, Lacombe V, Dieu X, Geneviève F, Urbanski G. Accurate stratification between VEXAS syndrome and differential diagnoses by deep learning analysis of peripheral blood smears. Clin Chem Lab Med. 2023 Feb 2. doi: 10.1515/cclm-2022-1283.

Lacombe, V., Beucher, A., Urbanski, G., Le Corre, Y., Cottin, L., Croué, A., Bouvier, A., 2022. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome. Exp Hematol Oncol 11, 6.

Desprez, C., Riou, J., Peterlin, P., Marchand, T., Couturier, M.-A., Villate, A., Mear, J.-B., Chevalier, P., Guillerm, G., Gyan, E., Schmidt-Tanguy, A., Walter, R.B., Hunault-Berger, M., Orvain, C., 2022. Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study. Leukemia 36, 2408–2417.



Chabrun F, Lacombe V, Dieu X, Geneviève F, Urbanski G. Accurate stratification between VEXAS syndrome and differential diagnoses by deep learning analysis of peripheral blood smears. Clin Chem Lab Med. 2023 Feb 2. doi: 10.1515/cclm-2022-1283.

_______________________________________________2022 ________________________________________________

Desprez, C., Riou, J., Peterlin, P., Marchand, T., Couturier, M.-A., Villate, A., Mear, J.-B., Chevalier, P., Guillerm, G., Gyan, E., Schmidt-Tanguy, A., Walter, R.B., Hunault-Berger, M., Orvain, C., 2022. Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study. Leukemia 36, 2408–2417.

Drevin, G., Briet, M., Bazzoli, C., Gyan, E., Schmidt, A., Dombret, H., Orvain, C., Giltat, A., Recher, C., Ifrah, N., Guardiola, P., Hunault-Berger, M., Abbara, C., 2022. Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics 14, 792.

Dulucq, S., Nicolini, F.E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., Guerci-Bresler, A., Legros, L., Ianotto, J.-C., Gardembas, M., Turlure, P., Dubruille, V., Rousselot, P., Martiniuc, J., Jardel, H., Johnson-Ansah, H., Joly, B., Henni, T., Cayssials, E., Zunic, P., Berger, M.G., Villemagne, B., Robbesyn, F., Morisset, S., Mahon, F.-X., Etienne, G., 2022. Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial. haematol 107, 2859–2869.

Gyan, E., Pigneux, A., Hunault, M., Peterlin, P., Carré, M., Bay, J.-O., Bonmati, C., Gallego-Hernanz, M.-P., Lioure, B., Bertrand, P., Vallet, N., Ternant, D., Darrouzain, F., Picou, F., Béné, M.-C., Récher, C., Hérault, O., 2022. Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML. Sci Rep 12, 9748.

Lacombe, V., Beucher, A., Urbanski, G., Le Corre, Y., Cottin, L., Croué, A., Bouvier, A., 2022. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome. Exp Hematol Oncol 11, 6.

Lemoine, S., Mornet, C., Quintin-Roue, I., Rousselet, M.-C., Cottin, L., Georgeais, A., Dubouis, L., Boyer, F., Orvain, C., Caillon, C., Renard, M., Le Brun, V., Le Clech, L., Ianotto, J.-C., Génin, E., Burroni, B., Ugo, V., Paz, D.L., Lippert, E., 2022. Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis. haematol 107, 2725–2731.

Passet, M., Kim, R., Gachet, S., Sigaux, F., Chaumeil, J., Galland, A., Sexton, T., Quentin, S., Hernandez, L., Larcher, L., Bergugnat, H., Ye, T., Karasu, N., Caye, A., Heizmann, B., Duluc, I., Chevallier, P., Rousselot, P., Huguet, F., Leguay, T., Hunault, M., Pflumio, F., Freund, J.-N., Lobry, C., Lhéritier, V., Dombret, H., Domon-Dell, C., Soulier, J., Boissel, N., Clappier, E., 2022. Concurrent CDX2 cis -deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. Blood 139, 3505–3518.

Roux, B., Picou, F., Debeissat, C., Koubi, M., Gallay, N., Hirsch, P., Ravalet, N., Béné, M.C., Maigre, M., Hunault, M., Mosser, J., Etcheverry, A., Gyan, E., Delhommeau, F., Domenech, J., Herault, O., 2022. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia. Cancer Gene Ther 29, 1263–1275.

Sureau, L., Buors, C., Ianotto, J.-C., Boyer, F., Tanguy-Schmidt, A., Roy, L., Cayssials, E., Cailly, L., Chomel, J.-C., Chauveau, A., Orvain, C., Mansier, O., Ranta, D., Robles, M., Gyan, E., Hérault, O., Nimubona, S., Marchand, T., Lippert, E., Riou, J., Ugo, V., Luque Paz, D., 2022. JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes. Blood Cancer J. 12, 56.

_______________________________________________2021 ________________________________________________

Baroud, M., Lepeltier, E., Thepot, S., El-Makhour, Y., Duval, O., 2021. The evolution of nucleosidic analogues: self-assembly of prodrugs into nanoparticles for cancer drug delivery. Nanoscale Adv. 3, 2157–2179.

Couturier, M.-A., Thomas, X., Raffoux, E., Huguet, F., Berthon, C., Simand, C., Gallego-Hernanz, M.-P., Hicheri, Y., Hunault Berger, M., Saillard, C., Leguay, T., Loiseau, C., Béné, M.-C., Chevallier, P., 2021. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Leuk Lymphoma 62, 620–629.


Foucault, A., Vallet, N., Ravalet, N., Picou, F., Bene, M.C., Gyan, E., Herault, O., 2021. Occupational pesticide exposure increases risk of acute myeloid leukemia: a meta-analysis of case–control studies including 3,955 cases and 9,948 controls. Sci Rep 11, 2007.

Foucault, A., Ravalet, N., Besombes, J., Picou, F., Gallay, N., Babin, L., Bourgeais, J., Hamard, S., Domenech, J., Loyer, P., Vallet, N., Lejeune, J., Gyan, E., Béné, M.C., Vallette, F., Olivier, C., Hérault, O., 2021. Low-Dose Pesticides Alter Primary Human Bone Marrow Mesenchymal Stem/Stromal Cells through ALDH2 Inhibition. Cancers 13, 5699.

Lacombe, V., Prevost, M., Bouvier, A., Thépot, S., Chabrun, F., Kosmider, O., Lacout, C., Beucher, A., Lavigne, C., Geneviève, F., Urbanski, G., 2021. Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold. Br J Haematol 195, 286–289.

Lacombe, V., Nunes Gomes, C., Robin, J., Thépot, S., François, S., Cottin, L., Ugo, V., Dieu, X., Abgueguen, P., Daniel, V., Giltat, A., Hunault, M., Riou, J., Orvain, C., Schmidt, A., 2021. Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations. Eur J Haematol 107, 489–496.

Lemoine, S., Renard, M., Bouvier, A., Orvain, C., Giltat, A., Cottin, L., Blanchet, O., Hunault-Berger, M., Ugo, V., Luque Paz, D., 2021. No detection of atypical one-base deletion of CALR exon 9 with fragment analysis: A molecular trap to avoid. Blood Cells, Molecules, and Diseases 90, 102589.

Luque Paz, D., Cottin, L., Lippert, E., Robin, J.-B., Bescond, C., Genevieve, F., Boyer, F., Quintin-Roue, I., Rousselet, M.-C., Burroni, B., Hunault-Berger, M., Ugo, V., Ianotto, J.-C., Orvain, C., 2021. Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic/early primary myelofibrosis, and overt primary myelofibrosis. Ann Hematol.

Peterlin, P., Gaschet, J., Guillaume, T., Garnier, A., Eveillard, M., Le Bourgeois, A., Cherel, M., Debord, C., Le Bris, Y., Theisen, O., Godon, C., Mahé, B., Dubruille, V., Wuilleme, S., Touzeau, C., Gastinne, T., Blin, N., Lok, A., Tessoulin, B., Le Gouill, S., Moreau, P., Béné, M.-C., Chevallier, P., 2021. A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia. Cancer Med 10, 642–648.


Ravalet, N., Foucault, A., Picou, F., Gombert, M., Renoult, E., Lejeune, J., Vallet, N., Lachot, S., Rault, E., Gyan, E., Bene, M.C., Herault, O., 2021. Automated Early Detection of Myelodysplastic Syndrome within the General Population Using the Research Parameters of Beckman-Coulter DxH 800 Hematology Analyzer. Cancers (Basel) 13.

Sureau, L., Orvain, C., Ianotto, J.-C., Ugo, V., Kiladjian, J.-J., Luque Paz, D., Riou, J., 2021. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. Blood Cancer J. 11, 135.

Tondeur, S., Paul, F., Riou, J., Mansier, O., Ranta, D., Le Clech, L., Lippert, E., Tavitian, S., Chaoui, D., Mercier, M., De Renzis, B., Cottin, L., Cassinat, B., Chrétien, J.-M., Ianotto, J.-C., Allangba, O., Marzac, C., Voillat, L., Boyer, F., Orvain, C., Hunault-Berger, M., Girodon, F., Kiladjian, J.-J., Ugo, V., Luque Paz, D., 2021. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study. Leukemia 35, 871–875.

_______________________________________________2020 ________________________________________________

Baccini, V., Geneviève, F., Jacqmin, H., Chatelain, B., Girard, S., Wuilleme, S., Vedrenne, A., Guiheneuf, E., Toussaint-Hacquard, M., Everaere, F., Soulard, M., Lesesve, J.-F., Bardet, V., 2020. Platelet Counting: Ugly Traps and Good Advice. Proposals from the French-Speaking Cellular Hematology Group (GFHC). JCM 9, 808.

Bouvier, A., Riou, J., Thépot, S., Sutra Del Galy, A., François, S., Schmidt, A., Orvain, C., Estienne, M.-H., Villate, A., Luque Paz, D., Cottin, L., Ribourtout, B., Beucher, A., Delneste, Y., Ifrah, N., Ugo, V., Hunault-Berger, M., Blanchet, O., 2020. Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation. Leukemia 34, 1342–1353.

Cottin, L., Riou, J., Orvain, C., Ianotto, J.C., Boyer, F., Renard, M., Truchan‐Graczyk, M., Murati, A., Jouanneau‐Courville, R., Allangba, O., Mansier, O., Burroni, B., Rousselet, M.-C., Quintin‐Roué, I., Martin, A., Sadot‐Lebouvier, S., Delneste, Y., Chrétien, J., Hunault‐Berger, M., Blanchet, O., Lippert, E., Ugo, V., Luque Paz, D., 2020. Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. Br J Haematol 188, 935–944.

El-Khoury, M., Cabagnols, X., Mosca, M., Vertenoeil, G., Marzac, C., Favale, F., Bluteau, O., Lorre, F., Tisserand, A., Rabadan Moraes, G., Ugo, V., Ianotto, J.-C., Rey, J., Solary, E., Roy, L., Rameau, P., Debili, N., Pasquier, F., Casadevall, N., Marty, C., Constantinescu, S.N., Raslova, H., Vainchenker, W., Plo, I., 2020. Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. Oncogene 39, 5323–5337.

Feriel, J., Depasse, F., Geneviève, F., 2020. How I investigate basophilia in daily practice. Int J Lab Hem 42, 237–245.

Kouzi, F., Zibara, K., Bourgeais, J., Picou, F., Gallay, N., Brossaud, J., Dakik, H., Roux, B., Hamard, S., Le Nail, L.-R., Hleihel, R., Foucault, A., Ravalet, N., Rouleux-Bonnin, F., Gouilleux, F., Mazurier, F., Bene, M.C., Akl, H., Gyan, E., Domenech, J., El-Sabban, M., Herault, O., 2020. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. Oncogene 39, 1198–1212.

Paillassa, J., Cornet, E., Noel, S., Tomowiak, C., Lepretre, S., Vaudaux, S., Dupuis, J., Devidas, A., Joly, B., Petitdidier-Lionnet, C., Haiat, S., Mariette, C., Thieblemont, C., Decaudin, D., Validire-Charpy, P., Drenou, B., Eisenmann, J.-C., Uribe, M.O., Olivrie, A., Touati, M., Lambotte, O., Hermine, O., Karsenti, J.-M., Feugier, P., Vaillant, W., Gutnecht, J., Lippert, E., Huysman, F., Ghomari, K., Boubaya, M., Levy, V., Riou, J., Damaj, G., Tanguy-Schmidt, A., Hunault-Berger, M., Troussard, X., 2020. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 10, 62.

Luque Paz, D., Jouanneau-Courville, R., Riou, J., Ianotto, J.-C., Boyer, F., Chauveau, A., Renard, M., Chomel, J.-C., Cayssials, E., Gallego-Hernanz, M.-P., Pastoret, C., Murati, A., Courtier, F., Rousselet, M.-C., Quintin-Roué, I., Cottin, L., Orvain, C., Thépot, S., Chrétien, J.-M., Delneste, Y., Ifrah, N., Blanchet, O., Hunault-Berger, M., Lippert, E., Ugo, V., 2020. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Advances 4, 4887–4897.

Orvain, C., Balsat, M., Tavernier, E., Marolleau, J.-P., Pabst, T., Chevallier, P., de Gunzburg, N., Cacheux, V., Rigal-Huguet, F., Chantepie, S., Caillot, D., Chalandon, Y., Frayfer, J., Bonmati, C., Lheritier, V., Ifrah, N., Dombret, H., Boissel, N., Hunault-Berger, M., 2020. Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study. Blood blood.2020004919.

Vantyghem, S., Peterlin, P., Thépot, S., Ménard, A., Dubruille, V., Debord, C., Guillaume, T., Garnier, A., Le Bourgeois, A., Wuilleme, S., Godon, C., Theisen, O., Eveillard, M., Delaunay, J., Maisonneuve, H., Morineau, N., Villemagne, B., Vigouroux, S., Subiger, F., Lestang, E., Loirat, M., Parcelier, A., Godmer, P., Mercier, M., Trebouet, A., Luque Paz, D., Le Calloch, R., Le Clech, L., Bossard, C., Moreau, A., Ugo, V., Hunault, M., Moreau, P., Le Gouill, S., Chevallier, P., Béné, M.C., Le Bris, Y., 2020. Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. Haematologica haematol.2019.242677.

_______________________________________________2019 ________________________________________________

Beucher, A., Dib, M., Orvain, C., Bouvier, A., Jouanneau‐Courville, R., Dobo, I., Cottin, L., Guardiola, P., Rousselet, M., Blanchet, O., Hunault, M., Ugo, V., Luque Paz, D., 2019. Next generation sequencing redefines a triple negative essential thrombocythaemia as double‐positive with rare mutations on JAK 2 V617 and MPL W515 hotspots. Br J Haematol 186, 785–788.


Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., Perrier, P., Alsafadi, S., Wassef, M., Margueron, R., Rousseau, A., Droin, N., Cagnard, N., Kaltenbach, S., Winter, S., Kubasch, A.-S., Bouscary, D., Santini, V., Toma, A., Hunault, M., Stamatoullas, A., Gyan, E., Cluzeau, T., Platzbecker, U., Adès, L., Puy, H., Stern, M.-H., Karim, Z., Mayeux, P., Nemeth, E., Park, S., Ganz, T., Kautz, L., Kosmider, O., Fontenay, M., 2019. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med 11.

Cottin, L., Riou, J., Boyer, F., Bouvier, A., Zannetti, A., Blouet, A., Truchan-Graczyk, M., Jouanneau-Courville, R., Beucher, A., Ribourtout, B., Orvain, C., Hunault-Berger, M., Blanchet, O., Ugo, V., Luque Paz, D., 2019. WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis. Blood Cells, Molecules, and Diseases 75, 35–40.

Guénot, C., Lacombe, F., Allou, K., Dumezy, F., Feuillard, J., Geneviève, F., Guérin, E., Guy, J., Maynadié, M., Ballon, O.W., Preudhomme, C., Baruchel, A., Dombret, H., Ifrah, N., Béné, M.C., Groupe d’Etude Immunologique des Leucémies (GEIL), 2019. Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. Leukemia 33, 1814–1816.

Leveque, X., Hochane, M., Geraldo, F., Dumont, S., Gratas, C., Oliver, L., Gaignier, C., Trichet, V., Layrolle, P., Heymann, D., Herault, O., Vallette, F.M., Olivier, C., 2019. Low-Dose Pesticide Mixture Induces Accelerated Mesenchymal Stem Cell Aging In Vitro. Stem Cells 37, 1083–1094.

Luque Paz, D., Mansier, O., Riou, J., Conejero, C., Roy, L., Belkhodja, C., Ugo, V., Giraudier, S., 2019. Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: a single center prospective cohort experience. Haematologica 104, e134–e137.

Mheidly, K., Lamy De La Chapelle, T., Hunault, M., Benboubker, L., Benchalal, M., Moreau, P., Baugier de Materre, A., Decaux, O., Laribi, K., 2019. New insights in the treatment of patients with solitary bone plasmacytoma. Leuk Lymphoma 60, 2810–2813.

Picou, F., Vignon, C., Debeissat, C., Lachot, S., Kosmider, O., Gallay, N., Foucault, A., Estienne, M.-H., Ravalet, N., Bene, M.C., Domenech, J., Gyan, E., Fontenay, M., Herault, O., 2019. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Adv 3, 4271–4279.

Sébert, M., Renneville, A., Bally, C., Peterlin, P., Beyne-Rauzy, O., Legros, L., Gourin, M.-P., Sanhes, L., Wattel, E., Gyan, E., Park, S., Stamatoullas, A., Banos, A., Laribi, K., Jueliger, S., Bevan, L., Chermat, F., Sapena, R., Nibourel, O., Chaffaut, C., Chevret, S., Preudhomme, C., Adès, L., Fenaux, P., 2019. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica 104, 1565–1571.

Tanasi, I., Ba, I., Sirvent, N., Braun, T., Cuccuini, W., Ballerini, P., Duployez, N., Tanguy-Schmidt, A., Tamburini, J., Maury, S., Doré, E., Himberlin, C., Duclos, C., Chevallier, P., Rousselot, P., Bonifacio, M., Cavé, H., Baruchel, A., Dombret, H., Soulier, J., Landman-Parker, J., Boissel, N., Clappier, E., 2019. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood 134, 1351–1355.

_______________________________________________2018 ________________________________________________

Blouet, A., Rousselet, M.-C., Le Bris, Y., Ribourtout, B., Bouvier, A., Cottin, L., Jouanneau-Courville, R., Blanchet, O., Ugo, V., Luque Paz, D., 2018. Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia: HemaSphere 2, e29.

Bouvier, A., Ribourtout, B., François, S., Orvain, C., Luque Paz, D., Beucher, A., Guérard, A., Guardiola, P., Ugo, V., Blanchet, O., Geneviève, F., Schmidt, A., Hunault-Berger, M., 2018. Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 101, 570–574.

Dumas, P.-Y., Mansier, O., Prouzet-Mauleon, V., Koya, J., Villacreces, A., Brunet de la Grange, P., Luque Paz, D., Bidet, A., Pasquet, J.-M., Praloran, V., Salin, F., Kurokawa, M., Mahon, F.-X., Cardinaud, B., Lippert, E., 2018. MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms. BMC Cancer 18, 1098.

Garban, F., Guyard, A., Labussière, H., Bulabois, C.-E., Marchand, T., Mounier, C., Caillot, D., Bay, J.-O., Coiteux, V., Schmidt-Tanguy, A., Le Niger, C., Robin, C., Ladaique, P., Lapusan, S., Deconinck, E., Rolland, C., Foote, A.M., François, A., Jacquot, C., Tardivel, R., Tiberghien, P., Bosson, J.-L., Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group, 2018. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial. JAMA Oncol 4, 468–475.

Gillet, N., Fouquereau, E., Coillot, H., Bonnetain, F., Dupont, S., Moret, L., Anota, A., Colombat, P., 2018. Ethical leadership, professional caregivers’ well-being, and patients’ perceptions of quality of care in oncology. Eur J Oncol Nurs 33, 1–7.

Girerd, S., Tosca, L., Herault, O., Vignon, C., Biard, D., Aggoune, D., Dkhissi, F., Bonnet, M.L., Sorel, N., Desterke, C., Bennaceur-Griscelli, A., Tachdjian, G., Guilhot, F., Guilhot, J., Chomel, J.-C., Turhan, A.G., 2018. Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells. Biochem Biophys Res Commun 498, 715–722.

Huguet, F., Chevret, S., Leguay, T., Thomas, X., Boissel, N., Escoffre-Barbe, M., Chevallier, P., Hunault, M., Vey, N., Bonmati, C., Lepretre, S., Marolleau, J.-P., Pabst, T., Rousselot, P., Buzyn, A., Cahn, J.-Y., Lhéritier, V., Béné, M.C., Asnafi, V., Delabesse, E., Macintyre, E., Chalandon, Y., Ifrah, N., Dombret, H., for the Group of Research on Adult ALL (GRAALL), 2018. Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. J Clin Oncol 36, 2514–2523.

Ianotto, J.-C., Chauveau, A., Boyer-Perrard, F., Gyan, E., Laribi, K., Cony-Makhoul, P., Demory, J.-L., de Renzis, B., Dosquet, C., Rey, J., Roy, L., Dupriez, B., Knoops, L., Legros, L., Malou, M., Hutin, P., Ranta, D., Benbrahim, O., Ugo, V., Lippert, E., Kiladjian, J.-J., 2018. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica 103, 438–446.

Lacombe, F., Campos, L., Allou, K., Arnoulet, C., Delabarthe, A., Dumezy, F., Feuillard, J., Geneviève, F., Guérin, E., Guy, J., Jouault, H., Lepelley, P., Maynadié, M., Solly, F., Ballon, O.W., Preudhomme, C., Baruchel, A., Dombret, H., Ifrah, N., Béné, M.C., on behalf of the Groupe d’Etude Immunologique des Leucémies (GEIL), 2018. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematol Oncol 36, 422–428.

Le Bourgeois, A., Labopin, M., Leclerc, M., de Latour, R.P., Bourhis, J.-H., Ceballos, P., Orvain, C., Wallet, H.L., Bilger, K., Blaise, D., Rubio, M.-T., Guillaume, T., Mohty, M., Chevallier, P., Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, 2018. Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC. Oncotarget 9, 36603–36612.

Le Calloch, R., Lacut, K., Le Gall-Ianotto, C., Nowak, E., Abiven, M., Tempescul, A., Dalbies, F., Eveillard, J.-R., Ugo, V., Giraudier, S., Guillerm, G., Lippert, E., Berthou, C., Ianotto, J.-C., 2018. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study). Haematologica 103, 607–613.

Luque Paz, D., Boyer, F., Beucher, A., Bouvier, A., Jouanneau-Courville, R., Guardiola, P., Lambert, D., Delneste, Y., Hunault, M., Blanchet, O., Ugo, V., 2018. Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis. Blood Cells Mol Dis 71, 75–76.

Mansier, O., Luque Paz, D., Ianotto, J.-C., Le Bris, Y., Chauveau, A., Boyer, F., Conejero, C., Fitoussi, O., Riou, J., Adiko, D., Touati, M., Chauzeix, J., Viallard, J.-F., Béné, M.C., Giraudier, S., Ugo, V., Lippert, E., 2018. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol 93, E84–E86.

Mollard, L.-M., Chauveau, A., Boyer-Perrard, F., Douet-Guilbert, N., Houot, R., Quintin-Roué, I., Couturier, M.-A., Dagorne, A., Malou, M., Le Calloch, R., Luycx, O., Thepot, S., Hunault, M., Guillerm, G., Berthou, C., Ugo, V., Lippert, É., Ianotto, J.-C., 2018. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase. Leuk Lymphoma 59, 2812–2820.

Paillassa, J., Leguay, T., Thomas, X., Huguet, F., Audrain, M., Lheritier, V., Vianey-Saban, C., Acquaviva-Bourdain, C., Pagan, C., Dombret, H., Ifrah, N., Boissel, N., Hunault-Berger, M., 2018. Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial. Blood Cancer J 8, 45.

Pigneux, A., Béné, M.C., Salmi, L.-R., Dumas, P.-Y., Delaunay, J., Bonmati, C., Guièze, R., Luquet, I., Cornillet-Lefebvre, P., Delabesse, E., Ianotto, J.-C., Ojeda-Uribe, M., Hunault, M., Banos, A., Fornecker, L.M., Bernard, M., Jourdan, E., Vey, N., Zerazhi, H., Hishri, Y., Mineur, A., Asselineau, J., Delepine, R., Cahn, J.-Y., Ifrah, N., Récher, C., on behalf of the French Innovative Leukemia Organization, 2018. Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. J Clin Oncol 36, 3203–3210.

Poiré, X., Labopin, M., Polge, E., Passweg, J., Craddock, C., Blaise, D., Cornelissen, J.J., Volin, L., Russell, N.H., Socié, G., Michallet, M., Fegueux, N., Chevallier, P., Brecht, A., Hunault-Berger, M., Mohty, M., Esteve, J., Nagler, A., 2018. Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 103, 256–265.

_______________________________________________2017 ________________________________________________

Alloin, A.-L., Leverger, G., Dalle, J.-H., Galambrun, C., Bertrand, Y., Baruchel, A., Auvrignon, A., Gandemer, V., Ragu, C., Loundou, A., Bilhou-Nabera, C., Lafage-Pochitaloff, M., Dastugue, N., Nelken, B., Jubert, C., Rialland, F., Plat, G., Pochon, C., Vannier, J.-P., Rohrlich, P.-S., Kanold, J., Lutz, P., Sirvent, A., Oudin, C., Cuccuini, W., Michel, G., on behalf of the ELAM study group, 2017. Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience. Bone Marrow Transplant 52, 516–521.

Bergeron, A., Chevret, S., Granata, A., Chevallier, P., Vincent, L., Huynh, A., Tabrizi, R., Labussiere-Wallet, H., Bernard, M., Chantepie, S., Bay, J.-O., Thiebaut-Bertrand, A., Thepot, S., Contentin, N., Fornecker, L.-M., Maillard, N., Risso, K., Berceanu, A., Blaise, D., Peffault de La Tour, R., Chien, J.W., Coiteux, V., Socié, G., ALLOZITHRO Study Investigators, 2017. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. JAMA 318, 557–566.

Cahu, X., Carré, M., Recher, C., Pigneux, A., Hunault-Berger, M., Vey, N., Chevallier, P., Delaunay, J., Gyan, E., Lioure, B., Bonmati, C., Himberlin, C., Hicheri, Y., Guillerm, G., Didier, B., Larosa, F., Ojeda-Uribe, M., Bernard, M., Bene, M.C., Ifrah, N., Cahn, J.-Y., 2017. Impact of body-surface area on patients’ outcome in younger adults with acute myeloid leukemia. Eur J Haematol 98, 443–449.

Chauveau, A., Nibourel, O., Tondeur, S., Luque Paz, D., Mansier, O., Paul, F., Wemeau, M., Preudhomme, C., Lippert, E., Ugo, V., 2017. Absence of CALR mutations in JAK2 -negative polycythemia. Haematologica 102, e15–e16.

Chevalier, S., Lejeune, J., Fouquereau, E., Coillot, H., Gillet, N., Gandemer, V., Michon, J., Colombat, P., 2017. Organizational and Managerial Resources and Quality of Care in French Pediatric Oncology Nursing. J Pediatr Oncol Nurs 34, 406–413.

Chevallier, P., Chantepie, S., Huguet, F., Raffoux, E., Thomas, X., Leguay, T., Marchand, T., Isnard, F., Charbonnier, A., Maury, S., Gallego-Hernanz, M.-P., Robillard, N., Guillaume, T., Peterlin, P., Garnier, A., Rialland, F., Le Houerou, C., Goldenberg, D.M., Wegener, W.A., Béné, M.-C., Dombret, H., 2017. Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. Haematologica 102, e184–e186.

Chretien, A.-S., Devillier, R., Fauriat, C., Orlanducci, F., Harbi, S., Le Roy, A., Rey, J., Bouvier Borg, G., Gautherot, E., Hamel, J.-F., Ifrah, N., Lacombe, C., Cornillet-Lefebvre, P., Delaunay, J., Toubert, A., Arnoulet, C., Vey, N., Blaise, D., Olive, D., 2017a. NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. Oncoimmunology 6, e1307491.

Chretien, A.-S., Fauriat, C., Orlanducci, F., Galseran, C., Rey, J., Bouvier Borg, G., Gautherot, E., Granjeaud, S., Hamel-Broza, J.-F., Demerle, C., Ifrah, N., Lacombe, C., Cornillet-Lefebvre, P., Delaunay, J., Toubert, A., Gregori, E., Luche, H., Malissen, M., Arnoulet, C., Nunes, J.A., Vey, N., Olive, D., 2017b. Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. Front. Immunol. 8, 573.

Desbourdes, L., Javary, J., Charbonnier, T., Ishac, N., Bourgeais, J., Iltis, A., Chomel, J.-C., Turhan, A., Guilloton, F., Tarte, K., Demattei, M.-V., Ducrocq, E., Rouleux-Bonnin, F., Gyan, E., Hérault, O., Domenech, J., 2017. Alteration Analysis of Bone Marrow Mesenchymal Stromal Cells from De Novo Acute Myeloid Leukemia Patients at Diagnosis. Stem Cells Dev 26, 709–722.

Douet-Guilbert, N., Chauveau, A., Gueganic, N., Guillerm, G., Tous, C., Le Bris, M.-J., Basinko, A., Morel, F., Ugo, V., De Braekeleer, M., 2017. Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic insertion of cbfb resulting in cbfb-Myh11 fusion: Cryptic ins(16) in AML. Hematol Oncol 35, 385–389.

Fausser, J.-L., Tavenard, A., Rialland, F., Le Moine, P., Minckes, O., Jourdain, A., Tirel, O., Pellier, I., Gandemer, V., 2017. Should We Pay Attention to the Delay Before Admission to a Pediatric Intensive Care Unit for Children With Cancer? Impact on 1-Month Mortality. A Report From the French Children’s Oncology Study Group, GOCE: J Pediatr Hematol Onco 39, e244–e248.

Hunault-Berger, M., Maillard, N., Himberlin, C., Recher, C., Schmidt-Tanguy, A., Choufi, B., Bonmati, C., Carré, M., Couturier, M.-A., Daguindau, E., Marolleau, J.-P., Orsini-Piocelle, F., Delaunay, J., Tavernier, E., Lissandre, S., Ojeda-Uribe, M., Sanhes, L., Sutton, L., Banos, A., Fornecker, L.M., Bernard, M., Bouscary, D., Saad, A., Puyade, M., Rouillé, V., Luquet, I., Béné, M.C., Hamel, J.-F., Dreyfus, F., Ifrah, N., Pigneux, A., for the FILO Group, 2017. Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial. Blood Cancer J. 7, e568–e568.

Ianotto, J.-C., Chauveau, A., Mottier, D., Ugo, V., Berthou, C., Lippert, E., Delluc, A., 2017. JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort. Ann Hematol 96, 383–386.

Lafage-Pochitaloff, M., Baranger, L., Hunault, M., Cuccuini, W., Lefebvre, C., Bidet, A., Tigaud, I., Eclache, V., Delabesse, E., Bilhou-Nabéra, C., Terré, C., Chapiro, E., Gachard, N., Mozziconacci, M.-J., Ameye, G., Porter, S., Grardel, N., Béné, M.C., Chalandon, Y., Graux, C., Huguet, F., Lhéritier, V., Ifrah, N., Dombret, H., 2017. Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood 130, 1832–1844.

Le Gall‐Ianotto, C., Brenaut, E., Gouillou, M., Lacut, K., Nowak, E., Tempescul, A., Berthou, C., Ugo, V., Carré, J.L., Misery, L., Ianotto, J.C., 2017. Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. Br J Dermatol 176, 255–258.

Luque Paz, D., Chauveau, A., Boyer, F., Buors, C., Samaison, L., Cottin, L., Seegers, V., Férec, C., Le Maréchal, C., Gueguen, P., Lippert, E., Ianotto, J.-C., Ugo, V., 2017. Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome: Mutations associated with disease outcome in PV and ET. Genes Chromosomes Cancer 56, 354–362.

Pastoret, C., Houot, R., Llamas-Gutierrez, F., Boulland, M.-L., Marchand, T., Tas, P., Ly-Sunnaram, B., Gandemer, V., Lamy, T., Roussel, M., Fest, T., 2017. Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing. Leuk Lymphoma 58, 1008–1012.

Pigneux, A., Béné, M.C., Guardiola, P., Recher, C., Hamel, J.-F., Sauvezie, M., Harousseau, J.-L., Tournilhac, O., Witz, F., Berthou, C., Escoffre-Barbe, M., Guyotat, D., Fegueux, N., Himberlin, C., Hunault, M., Delain, M., Lioure, B., Jourdan, E., Bauduer, F., Dreyfus, F., Cahn, J.-Y., Sotto, J.-J., Ifrah, N., 2017. Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study. J Clin Oncol 35, 387–393.

_______________________________________________2016 ________________________________________________

Bond, J., Marchand, T., Touzart, A., Cieslak, A., Trinquand, A., Sutton, L., Radford-Weiss, I., Lhermitte, L., Spicuglia, S., Dombret, H., Macintyre, E., Ifrah, N., Hamel, J.-F., Asnafi, V., 2016. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Haematologica 101, 732–740.

Brissot, E., Rialland, F., Cahu, X., Strullu, M., Corradini, N., Thomas, C., Blin, N., Rialland, X., Thebaud, E., Chevallier, P., Moreau, P., Milpied, N., Harousseau, J.L., Mechinaud, F., Mohty, M., 2016. Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution. Bone Marrow Transplant 51, 267–272.

Cabagnols, X., Favale, F., Pasquier, F., Messaoudi, K., Defour, J.P., Ianotto, J.C., Marzac, C., Le Couédic, J.P., Droin, N., Chachoua, I., Favier, R., Diop, M.K., Ugo, V., Casadevall, N., Debili, N., Raslova, H., Bellanné-Chantelot, C., Constantinescu, S.N., Bluteau, O., Plo, I., Vainchenker, W., 2016. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood 127, 333–342.

Chauveau, A., Luque Paz, D., Lecucq, L., Le Gac, G., Le Maréchal, C., Gueguen, P., Berthou, C., Ugo, V., 2016. A new point mutation in EPOR inducing a short deletion in congenital erythrocytosis. Br J Haematol 172, 475–477.

Chevallier, P., Labopin, M., La Tour, R.P., Lioure, B., Bulabois, C., Huynh, A., Blaise, D., Turlure, P., Daguindau, E., Maillard, N., Yakoub‐Agha, I., Guillerm, G., Delage, J., Contentin, N., Bay, J., Beckerich, F., Bourhis, J., Detrait, M., Vigouroux, S., François, S., Legrand, F., Guillaume, T., Mohty, M., the SFGM‐TC, 2016. Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. Cancer Med 5, 3068–3076.

Desjonquères, A., Chevallier, P., Thomas, X., Huguet, F., Leguay, T., Bernard, M., Bay, J.-O., Tavernier, E., Charbonnier, A., Isnard, F., Hunault, M., Turlure, P., Renaud, M., Bastié, J.-N., Himberlin, C., Lepretre, S., Lioure, B., Lhéritier, V., Asnafi, V., Beldjord, K., Lafage-Pochitaloff, M., Béné, M.C., Ifrah, N., Dombret, H., on behalf of the French Group for Research in Adult ALL (GRAALL), 2016. Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood Cancer J 6, e504–e504.

Desjonqueres, A., Illiaquer, M., Duquesne, A., Le Bris, Y., Peterlin, P., Guillaume, T., Delaunay, J., Rialland, F., Moreau, P., Béné, M.C., Chevallier, P., Eveillard, M., 2016. Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation. Bone Marrow Transplant 51, 1150–1152.

Gillet, B., Ianotto, J.-C., Mingant, F., Didier, R., Gilard, M., Ugo, V., Lippert, E., Galinat, H., 2016. Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance. Thromb Res 142, 26–32.

Grain, A., Sirvent, A., Strullu, M., Françoise, M., Mohty, M., Guillaume, T., Chevallier, P., Rialland, F., 2016. Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-TC). Leuk Lymphoma 57, 2937–2941.

Guièze, R., Damaj, G., Pereira, B., Robin, M., Chevallier, P., Michallet, M., Vigouroux, S., Beguin, Y., Blaise, D., El Cheikh, J., Roos-Weil, D., Thiebaut, A., Rohrlich, P.-S., Huynh, A., Cornillon, J., Contentin, N., Suarez, F., Lioure, B., Mohty, M., Maillard, N., Clement, L., François, S., Guillerm, G., Yakoub-Agha, I., 2016. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies. Biol Blood Marrow Transplant 22, 240–247.

Haro, S., Tavenard, A., Rialland, F., Taque, S., Guillerm, G., Blouin, P., Esvan, M., Pellier, I., Gandemer, V., 2016. Keep in Mind Quality of Life: Outcome of a Ten-Year Series of Post-Transplantation Early Relapses in Childhood Acute Lymphoblastic Leukemia—A Report from the Grand Ouest Oncology Study Group for Children in France. Biol Blood Marrow Transplant 22, 889–894.

Ianotto, J.-C., Chauveau, A., Luque Paz, D., Delluc, A., Tromeur, C., Couturier, M.-A., Gouillou, M., Berthou, C., Mottier, D., Ugo, V., 2016. Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism. Thromb Haemost 115, 225–226.

Jaspers, A., Bouhya, S., Belaiche, S., Chevallier, P., Hermet, E., Hospital-Gustems, C., Michallet, M., Rialland, F., Samsonova, O., Sirvent, A., Yakoub-Agha, I., Rohrlich, P.-S., Beguin, Y., 2016. Évaluation et prise en charge de la surcharge en fer post-greffe : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 103, S255–S266.

Lepretre, S., Touzart, A., Vermeulin, T., Picquenot, J.-M., Tanguy-Schmidt, A., Salles, G., Lamy, T., Béné, M.-C., Raffoux, E., Huguet, F., Chevallier, P., Bologna, S., Bouabdallah, R., Benichou, J., Brière, J., Moreau, A., Tallon-Simon, V., Seris, S., Graux, C., Asnafi, V., Ifrah, N., Macintyre, E., Dombret, H., 2016. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol 34, 572–580.

Luque Paz, D., Ianotto, J.-C., Chauveau, A., Guibourg, B., Lecucq, L., Lippert, E., Ugo, V., 2016. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib. Ann Hematol 95, 349–350.

Mahé, K., Luque Paz, D., Couturier, M.-A., Chauveau, A., Quintin-Roué, I., Berthou, C., Ugo, V., Lippert, E., Ianotto, J.-C., 2016. Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 V617F and JAK2 exon 12 allele burden disappearance during the follow-up of two patients. Ann Hematol 95, 529–531.

Malard, F., Labopin, M., Chevallier, P., Guillaume, T., Duquesne, A., Rialland, F., Derenne, S., Peterlin, P., Leauté, A.-G., Brissot, E., Gregoire, M., Moreau, P., Saas, P., Gaugler, B., Mohty, M., 2016. Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. Blood 127, 1828–1835.

Maury, S., Chevret, S., Thomas, X., Heim, D., Leguay, T., Huguet, F., Chevallier, P., Hunault, M., Boissel, N., Escoffre-Barbe, M., Hess, U., Vey, N., Pignon, J.-M., Braun, T., Marolleau, J.-P., Cahn, J.-Y., Chalandon, Y., Lhéritier, V., Beldjord, K., Béné, M.C., Ifrah, N., Dombret, H., for GRAALL, 2016. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med 375, 1044–1053.

Michel, G., Galambrun, C., Sirvent, A., Pochon, C., Bruno, B., Jubert, C., Loundou, A., Yakoub-Agha, I., Milpied, N., Lutz, P., Marie-Cardine, A., Gandemer, V., Blaise, D., Michallet, M., Rialland, F., Renard, C., Oudin, C., Esmiol, S., Seux, M., Baumstarck, K., Mohty, M., Rocha, V., Dalle, J.-H., 2016. Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood 127, 3450–3457.

Nelken, B., Cave, H., Leverger, G., Galambrun, C., Plat, G., Schmitt, C., Thomas, C., Vérité, C., Brethon, B., Gandemer, V., Bertrand, Y., Baruchel, A., Rohrlich, P., 2016. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee). Pediatr Blood Cancer 63, 270–275.

Orvain, C., Luque Paz, D., Dobo, I., Cottin, L., Le Calvez, G., Chauveau, A., Mercier, M., Farhi, J., Boyer, F., Ianotto, J.C., Guibourg, B., Rousselet, M.C., Zandecki, M., Ifrah, N., Hunault-Berger, M., Ugo, V., Genevieve, F., 2016. Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. Ann Hematol 95, 1819–1823.

Ravinet, A., Cabrespine, A., Socié, G., Milpied, N., Yakoub Agha, I., Nguyen, S., Michallet, M., Menard, A.L., Maillard, N., Mohty, M., Suarez, F., Huynh, A., Marchand, T., Deteix, C., Cassuto, J.P., Maury, S., Chevallier, P., Reman, O., Peffault de Latour, R., Bay, J.O., 2016. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Transplantation 100, 1732–1739.

Rousselot, P., Coudé, M.M., Gokbuget, N., Gambacorti Passerini, C., Hayette, S., Cayuela, J.-M., Huguet, F., Leguay, T., Chevallier, P., Salanoubat, C., Bonmati, C., Alexis, M., Hunault, M., Glaisner, S., Agape, P., Berthou, C., Jourdan, E., Fernandes, J., Sutton, L., Banos, A., Reman, O., Lioure, B., Thomas, X., Ifrah, N., Lafage-Pochitaloff, M., Bornand, A., Morisset, L., Robin, V., Pfeifer, H., Delannoy, A., Ribera, J., Bassan, R., Delord, M., Hoelzer, D., Dombret, H., Ottmann, O.G., 2016. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL. Blood 128, 774–782.

Visentin, S., Auquier, P., Bertrand, Y., Baruchel, A., Tabone, M.-D., Pochon, C., Jubert, C., Poirée, M., Gandemer, V., Sirvent, A., Bonneau, J., Paillard, C., Freycon, C., Kanold, J., Villes, V., Berbis, J., Oudin, C., Galambrun, C., Pellier, I., Plat, G., Chambost, H., Leverger, G., Dalle, J.-H., Michel, G., 2016. The Impact of Donor Type on Long-Term Health Status and Quality of Life after Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Leucémie de l’Enfant et de L’Adolescent Study. Biol Blood Marrow Transplant 22, 2003–2010.

_______________________________________________2015 ________________________________________________

Boissel, N., Renneville, A., Leguay, T., Lefebvre, P.C., Recher, C., Lecerf, T., Delabesse, E., Berthon, C., Blanchet, O., Prebet, T., Pautas, C., Chevallier, P., Leprêtre, S., Girault, S., Bonmati, C., Guièze, R., Himberlin, C., Randriamalala, E., Preudhomme, C., Jourdan, E., Dombret, H., Ifrah, N., 2015. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica 100, 780–785.

Cabagnols, X., Defour, J.P., Ugo, V., Ianotto, J.C., Mossuz, P., Mondet, J., Girodon, F., Alexandre, J.H., Mansier, O., Viallard, J.F., Lippert, E., Murati, A., Mozziconacci, M.J., Saussoy, P., Vekemans, M.C., Knoops, L., Pasquier, F., Ribrag, V., Solary, E., Plo, I., Constantinescu, S.N., Casadevall, N., Vainchenker, W., Marzac, C., Bluteau, O., 2015. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 29, 249–252.

Chalandon, Y., Thomas, X., Hayette, S., Cayuela, J.-M., Abbal, C., Huguet, F., Raffoux, E., Leguay, T., Rousselot, P., Lepretre, S., Escoffre-Barbe, M., Maury, S., Berthon, C., Tavernier, E., Lambert, J.-F., Lafage-Pochitaloff, M., Lhéritier, V., Chevret, S., Ifrah, N., Dombret, H., 2015. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 125, 3711–3719.

Chevallier, P., Eugene, T., Robillard, N., Isnard, F., Nicolini, F., Escoffre-Barbe, M., Huguet, F., Hunault, M., Marcais, A., Gaschet, J., Cherel, M., Guillaume, T., Delaunay, J., Peterlin, P., Eveillard, M., Thomas, X., Ifrah, N., Lapusan, S., Bodet-Milin, C., Barbet, J., Faivre-Chauvet, A., Ferrer, L., Bene, M.C., Le Houerou, C., Goldenberg, D.M., Wegener, W.A., Kraeber-Bodéré, F., 2015a. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol 2, e108-117.

Chevallier, P., Labopin, M., Socie, G., Rubio, M.-T., Blaise, D., Vigouroux, S., Huynh, A., Michallet, M., Bay, J.-O., Maury, S., Yakoub-Agha, I., Fegueux, N., Deconinck, E., Contentin, N., Maillard, N., Bulabois, C.-E., Francois, S., Oumedaly, R., Raus, N., Mohty, M., 2015b. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. Eur J Haematol 94, 449–455.

Chien, W.W., Catallo, R., Chebel, A., Baranger, L., Thomas, X., Béné, M.-C., Gerland, L.M., Schmidt, A., Beldjord, K., Klein, N., Escoffre-Barbe, M., Leguay, T., Huguet, F., Larosa, F., Hayette, S., Plesa, A., Ifrah, N., Dombret, H., Salles, G., Chassevent, A., Ffrench, M., 2015. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. Leuk Res 39, 453–461.

Couturier, M.-A., Huguet, F., Chevallier, P., Suarez, F., Thomas, X., Escoffre-Barbe, M., Cacheux, V., Pignon, J.-M., Bonmati, C., Sanhes, L., Bories, P., Daguindau, E., Dorvaux, V., Reman, O., Frayfer, J., Orvain, C., Lhéritier, V., Ifrah, N., Dombret, H., Hunault-Berger, M., Tanguy-Schmidt, A., 2015. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l -asparaginase: The GRAALL experience: Incidence, Risk Factors, and Management of CNS Thrombosis. Am. J. Hematol. 90, 986–991.

Dhédin, N., Huynh, A., Maury, S., Tabrizi, R., Beldjord, K., Asnafi, V., Thomas, X., Chevallier, P., Nguyen, S., Coiteux, V., Bourhis, J.-H., Hichri, Y., Escoffre-Barbe, M., Reman, O., Graux, C., Chalandon, Y., Blaise, D., Schanz, U., Lhéritier, V., Cahn, J.-Y., Dombret, H., Ifrah, N., 2015. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood 125, 2486–2496.

Fossat, C., Roussel, M., Arnoux, I., Asnafi, V., Brouzes, C., Garnache-Ottou, F., Jacob, M.C., Kuhlein, E., Macintyre-Davi, E., Plesa, A., Robillard, N., Tkaczuk, J., Ifrah, N., Dombret, H., Béné, M.C., Baruchel, A., Garand, R., for the French Multicenter Study Groups for Pediatric and Adult ALL, 2014. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study: Cytometry. Part B, Clinical Cytometry 8821-29.

Huet, S., Dulucq, S., Chauveau, A., Ménard, A., Chomel, J.-C., Maisonneuve, H., Legros, L., Perrin, M.-C., Ferrant, E., Moreilhon, C., Couturier, M.-A., Sujobert, P., Magaud, J.-P., Ugo, V., Chabane, K., Raynaud, S., Hayette, S., GBMHM (Groupe des Biologistes Moléculaires des Hémopathies Malignes, French Molecular Biology Group in Hematology), 2015. Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts: Characterization of five new BCR-ABL1 transcripts. Genes Chromosomes Cancer 54, 595–605.

Hunault-Berger, M., Leguay, T., Huguet, F., Leprêtre, S., Deconinck, E., Ojeda-Uribe, M., Bonmati, C., Escoffre-Barbe, M., Bories, P., Himberlin, C., Chevallier, P., Rousselot, P., Reman, O., Boulland, M.-L., Lissandre, S., Turlure, P., Bouscary, D., Sanhes, L., Legrand, O., Lafage-Pochitaloff, M., Béné, M.C., Liens, D., Godfrin, Y., Ifrah, N., Dombret, H., Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL), 2015. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study: L-asparaginase within erythrocytes in elderly ALL patients. Am. J. Hematol. 90, 811–818.

Itzykson, R., Thépot, S., Berthon, C., Delaunay, J., Bouscary, D., Cluzeau, T., Turlure, P., Prébet, T., Dartigeas, C., Marolleau, J.-P., Recher, C., Plantier, I., Stamatoullas, A., Devidas, A., Taksin, A.-L., Guièze, R., Caillot, D., Vey, N., Adès, L., Ifrah, N., Dombret, H., Fenaux, P., Gardin, C., 2015. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res 39, 124–130.

Verger, E., Cassinat, B., Chauveau, A., Dosquet, C., Giraudier, S., Schlageter, M.-H., Ianotto, J.-C., Yassin, M.A., Al-Dewik, N., Carillo, S., Legouffe, E., Ugo, V., Chomienne, C., Kiladjian, J.-J., 2015. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood 126, 2585–2591.

bottom of page